Spinoculation is a laboratory technique in which cells and virus particles are centrifuged together, using gentle centrifugal force to push viral particles onto cell surfaces and dramatically improve the rate at which viruses enter those cells. The method is widely used in gene therapy manufacturing, virology research, and genome-wide screening experiments. What makes it interesting, and why researchers keep returning to it decades after its introduction, is that such a simple physical trick can boost viral transduction from modest single-digit percentages to rates that would otherwise require far more virus or much more complex engineering.
How Spinoculation Works
Under normal lab conditions, when you mix virus particles with target cells in a dish or a bag, the two bump into each other mostly by random diffusion. Virus particles are tiny, and the fluid they float in is vast relative to their size. Most of the virus never reaches a cell surface during a typical incubation window. Spinoculation changes the math by applying centrifugal force, effectively pushing the viral particles downward onto the cells sitting at the bottom of a tube or plate. Early work on HIV showed that centrifuging virus and target T cells together at a moderate force for two hours increased the number of viral particles that actually bound to cells by roughly 40-fold compared to simply mixing the two together and letting them sit.1PubMed Central. Human immunodeficiency virus type 1 spinoculation enhances infection through virus binding That study found that after culturing the spinoculated samples for 24 hours, essentially 100% of the target cells became productively infected.
The core idea is straightforward: diffusion is the bottleneck. In a static incubation, viral particles wander randomly through the liquid medium, and only a fraction will drift close enough to a cell surface to attach and infect. The centrifugal force used in spinoculation is modest by laboratory standards, but it is enough to sediment viral particles out of suspension and deposit them directly onto cells. Researchers confirmed this by showing that antibodies blocking the cell’s viral receptor still prevented infection during spinoculation, which means the virus is still using its normal entry machinery. The centrifuge just gets the virus to the doorstep faster.
More Than Just Pushing Particles Down
For years, the explanation stopped there: centrifuge pushes virus onto cells, more virus lands, more infection happens. But research into the cellular side of the equation revealed something more nuanced. Spinoculation triggers changes inside the cell itself. When T cells are centrifuged, they respond to the mechanical stress by reorganizing their internal scaffolding, specifically the actin filaments that control cell shape and movement. This actin activity leads to increased surface expression of the receptors that HIV uses to enter the cell, meaning the cells essentially become more receptive to viral binding and entry during the spin.2PubMed Central. Spinoculation triggers dynamic actin and cofilin activity that facilitates HIV-1 infection of transformed and resting CD4 T cells
So spinoculation is a two-for-one deal. It physically deposits viral particles onto cell surfaces, and it primes the cells to be more susceptible to viral entry. This dual effect helps explain why the technique works so well across such a wide range of cell types and viral vectors, not just in the HIV research context where it was first studied in detail.
Finding the Sweet Spot for Speed and Duration
Not all spinoculation protocols are created equal. The two main dials researchers can turn are the centrifugal force (measured in multiples of gravitational force, or “g”) and the duration of the spin. Getting these right matters because too little force and you lose the efficiency gain, while too much or too long and you risk stressing the cells without meaningful extra benefit.
A study optimizing transduction in primary immune cells found that spinning at 2,000 × g enhanced transduction roughly sixfold compared to no spinning at all, and cell growth was not reduced even at that force.3PubMed Central. Optimized conditions for gene transduction into primary immune cells using viral vectors For T cells, 90 minutes of spinning produced the best transduction; for natural killer cells, 60 minutes was optimal. In both cases, efficiency scaled roughly in proportion to spin time up to those peaks.
Work focused specifically on CAR T-cell manufacturing found a similar pattern but with a slightly different optimum. Increasing the spin speed from standard levels to 2,000 g and 3,000 g improved the percentage of cells expressing the CAR gene to about 31–32%, but going higher to 4,000 g provided no additional benefit. For spin duration, 80 minutes was the sweet spot, outperforming both shorter spins of 20 or 40 minutes and a longer 120-minute cycle.4Molecular Therapy Advances. Impact of physical and chemical parameters on spinoculation for chimeric antigen receptor T cell manufacturing using a quality-by-design approach The longer spin actually performed worse, suggesting that extended centrifugation may begin to counteract the benefit, possibly through cell fatigue or other stress responses.
The practical takeaway for researchers designing protocols: there is a plateau. Cranking up either the speed or the time past a certain threshold does not keep improving results and may start degrading them. Most optimized protocols settle in the range of 1,000 to 2,000 g for 60 to 90 minutes, though the exact optimum shifts depending on the cell type and the viral vector being used.
Chemical Boosters That Pair with Spinning
Spinoculation is often combined with chemical transduction enhancers, small molecules or polymers that further increase the likelihood that viral particles will successfully enter cells. Two of the most common are polybrene and a newer product called LentiBOOST. These work through a different mechanism than the centrifuge: they neutralize the electrical charges that cause virus and cell surfaces to repel each other, or they otherwise facilitate the membrane fusion step.
In the CAR T-cell manufacturing study mentioned above, adding LentiBOOST alongside spinoculation roughly tripled the percentage of cells expressing the therapeutic gene, jumping from about 24% without any enhancer to about 57% with LentiBOOST at its optimal concentration. Polybrene approximately doubled expression under similar conditions.4Molecular Therapy Advances. Impact of physical and chemical parameters on spinoculation for chimeric antigen receptor T cell manufacturing using a quality-by-design approach However, when researchers optimized for the full package of outcomes they cared about, including cell health, growth rate, and the balance of different T-cell subtypes, the best overall protocol used LentiBOOST but dropped polybrene entirely. Polybrene boosted transduction but came with cytotoxicity that hurt cells downstream.
A broader analysis of the process confirmed this picture: enhancing cell-to-vector contact, whether through physical means like spinning or chemical means like LentiBOOST, is a more effective strategy than simply dumping in more virus. The optimized combined process roughly doubled transduction efficiency under standard conditions and nearly tripled it when serum-free and animal-product-free media were used, all without harming cell growth or function.4Molecular Therapy Advances. Impact of physical and chemical parameters on spinoculation for chimeric antigen receptor T cell manufacturing using a quality-by-design approach That last point matters for clinical manufacturing, where reducing the amount of expensive viral vector needed to achieve the same result translates directly into lower costs and simpler supply chains.
Why CAR T-Cell Manufacturing Relies on Spinoculation
The single biggest consumer of spinoculation today is the production of CAR T cells, an immunotherapy in which a patient’s own T cells are removed, genetically modified to recognize cancer cells, and then infused back. The genetic modification step typically involves a lentiviral vector that carries the CAR gene into the T cell. If that transduction step is inefficient, you either need more virus (expensive), more starting cells (hard to get from sick patients), or more time in culture (which can exhaust the T cells and make them less effective). Spinoculation helps on all three fronts by getting more virus into more cells per round.
One of the early clinical-scale validations of this approach involved T cells engineered to target CD19, a protein found on certain leukemia and lymphoma cells. In that manufacturing process, bags of cells and lentiviral vector were spinoculated for one hour at a relatively low force of 186 g, then transferred to an incubator to continue the infection process.5PubMed Central. Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy Even that gentle protocol was sufficient to produce functional CAR T cells at clinical scale.
Scaling spinoculation from research centrifuges to clinical manufacturing has its own challenges, though. A standard benchtop centrifuge works fine for a single tube or plate, but manufacturing a patient dose might involve hundreds of millions of cells in bags. Automated systems have been developed to address this. A one-hour spin on an automated closed-system device achieved transduction efficiency of about 83%, compared to roughly 73% for conventional bag centrifugation and just 36% for static incubation with no spinning at all.6PubMed Central. High efficiency closed-system gene transfer using automated spinoculation The automated approach also kept the system sealed from the outside environment throughout, which is important for maintaining the sterility required by regulators. And the resulting CAR T cells killed tumor targets just as effectively as those made by other methods, meaning the spinning did not compromise their therapeutic function.6PubMed Central. High efficiency closed-system gene transfer using automated spinoculation
Beyond Gene Therapy: CRISPR Screening and Virology
CAR T-cell production gets the most attention, but spinoculation is just as important in large-scale genetic screening experiments. In a genome-wide CRISPR knockout screen, researchers need to deliver a library containing tens of thousands of different guide RNAs into a population of cells, with each cell ideally receiving just one guide. This requires transducing a very large number of cells at a controlled, low rate of infection per cell. If transduction efficiency is too low overall, you need an impractically large starting population to ensure every guide in the library is represented. Spinoculation helps by pushing the baseline efficiency high enough that the experiment becomes feasible at manageable cell numbers.
A recent CRISPR screen aimed at identifying therapeutic targets in psoriasis used spinoculation to deliver a genome-wide knockout library into human skin cells, transducing at a carefully controlled level to ensure single-guide-per-cell representation.7Nature Communications. AI-guided CRISPR screening reveals therapeutic targets in psoriasis Without spinoculation or a comparable efficiency-boosting method, the sheer scale of virus and cells needed for such experiments would make them impractical for many labs.
In basic virology, spinoculation remains a workhorse for studying viral biology. It was originally developed in the context of HIV research, and it continues to be used whenever researchers need reproducible, near-complete infection of a cell population. When you need every cell in a dish infected for a mechanistic study, waiting for random diffusion to deliver virus to each cell is unreliable. Spinoculation makes high-level, uniform infection routine.
When Spinoculation Hurts Cells
The recurring reassurance in published studies is that spinoculation does not significantly harm cell viability or growth. For the most part, this holds: T cells, NK cells, and hematopoietic stem cells generally tolerate centrifugation at the forces and durations used in standard protocols. But the picture is not uniformly rosy, particularly for cells that are harder to transduce in the first place.
Work on suspension cell lines used in genome-wide CRISPR screening found that spinoculation, especially when combined with polybrene, was stressful enough to reduce cell viability and slow recovery for several days after the procedure.8bioRxiv. Overcoming lentiviral delivery limitations in hard-to-transduce suspension cells for genome-wide CRISPR screening The transduction efficiency within the surviving population was also less consistent, meaning some cells took up more virus than others, which is a problem for screens that depend on even representation. The evidence here is still preliminary, but it highlights that the standard “spin and add polybrene” recipe does not work universally and that optimizing for each specific cell type matters.
Patient-derived cells add another layer of variability. Cells from a person with cancer, for instance, may already be in poor shape before they reach the manufacturing facility. The spinoculation protocols optimized on healthy-donor cells may need to be gentler or shorter for patient samples. To their credit, several published manufacturing studies have explicitly tested patient-derived cells alongside healthy-donor material. The automated closed-system study noted that performance was consistent between healthy-donor and patient samples, which is encouraging but may not hold for all diseases or all patients.6PubMed Central. High efficiency closed-system gene transfer using automated spinoculation
What Might Eventually Replace It
Spinoculation is effective, but it is also somewhat crude. You are strapping bags of patient cells to a centrifuge rotor and spinning them, which is hard to standardize perfectly, hard to scale, and mechanically complex when integrated into fully enclosed manufacturing systems. Researchers have been exploring alternatives that achieve the same goal of forcing virus and cells together without centrifugal force.
One approach uses microfluidic devices, tiny channels that physically confine cells and virus particles into a small space and then push fluid through a membrane to drive the two together. A microfluidic transduction device demonstrated that it could improve lentiviral transduction of both T cells and blood stem cells by more than twofold compared to static controls, and it reached transduction saturation using only half the virus that static conditions required.7Nature Communications. AI-guided CRISPR screening reveals therapeutic targets in psoriasis The device did not harm viability or expansion, much like spinoculation, but with the advantage of being more amenable to continuous-flow manufacturing and easier to standardize.
Other groups are exploring acoustic focusing, electroporation-based delivery, and non-viral gene editing approaches that bypass viral vectors entirely. Each has its own trade-offs in efficiency, cell health, and scalability. For now, spinoculation remains the dominant method in clinical manufacturing workflows for viral vector-based therapies, largely because it is well-characterized, regulatory agencies have accepted it in approved manufacturing processes, and the equipment is already in place at most production sites. Replacements will need to match not just the transduction numbers but also the deep body of safety and consistency data that spinoculation has accumulated over two decades of use.
Protocols Vary More Than You Might Expect
One thing that surprises people encountering spinoculation for the first time is how much protocols differ from lab to lab and paper to paper. Some groups spin at 300 g for 30 minutes. Others go to 2,000 g for 90 minutes. Some use room temperature, others warm the centrifuge to 32°C. A protocol for editing gut organoids, for example, calls for spinning at just 600 g at 32°C for one hour, a much gentler approach than the high-force protocols used for T cells. The “right” protocol depends on the cell type, the viral vector, the downstream application, and how much stress the cells can tolerate.
This variability is both a strength and a weakness. It is a strength because it means spinoculation is flexible enough to be adapted to nearly any cell-virus system. It is a weakness because it means every new application essentially requires its own optimization campaign. The recent quality-by-design studies using statistical models to simultaneously optimize multiple parameters represent the field’s attempt to make this process more systematic rather than trial-and-error. The hope is that by mapping the landscape of speed, duration, and chemical enhancers for a given cell-vector combination, manufacturers can zero in on the best conditions more quickly and with greater confidence that the result will be reproducible at scale.9PubMed Central. Optimizing viral transduction in immune cell therapy manufacturing: key process design considerations
For researchers setting up spinoculation for the first time, the most common mistake is assuming a published protocol will transfer directly to their system without adjustment. Cell density, the ratio of virus to cells, the medium composition, and even the type of vessel used all interact with the physical spinning parameters. Starting with a well-established protocol and then systematically varying one parameter at a time is the standard approach, but even experienced labs occasionally find that moving to a new cell source or a different viral lot requires going back to the optimization step.